



## New Advances in Precision Medicine for Pituitary Tumors

Guest Editor:

### Dr. Cheol Ryong Ku

Department of Internal Medicine,  
Institute of Endocrine Research,  
Yonsei University College of  
Medicine, Seoul 03722, Korea

Deadline for manuscript  
submissions:

**closed (31 August 2022)**

### Message from the Guest Editor

Pituitary tumors are rare conditions which can cause the hormonal abnormality and the mass effect such as visual field defect. For treatment, there are three options: surgical resection, medical therapeutics, and radiotherapy. Because the clinical approach is moving toward value-based reimbursements, analyses for treatment cost-effectiveness and efficacies are required. Late diagnosis and management are a hurdle that necessitates the initiation of precision therapy, or customization of treatment, in everyday practice. Furthermore, cases of resistance to surgical or medical treatment require an integration of clinical and molecular predictors to aid in selecting the best tailored treatment. Simultaneous consideration of all predictors, such as the patient's gender, age, preoperative hormonal levels, tumor size, among others, plays a role in improving remission rates.

In this Special Issue, we publish reviews and original research that provide new insights into novel therapeutic targets, biomarkers associated with treatment responsiveness, and predictors of prognosis of pituitary tumors. Articles about multi-omics approaches will be particularly welcomed.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI